March 10, 2022 7:33am
I’m reacting, not waiting for the swing downward, count them alternately after every big bounce
Pre-open indications: 11 SELLs indications and 1 pimp/pump/promote
News: Intellia Therapeutics (NTLA pre-open -$0.68) Received U.S. FDA Orphan Drug Designation for NTLA-5001 for the treatment of Acute Myeloid Leukemia
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Only the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.88% (-293 points), S&P futures are DOWN -0.87% (-38 points) and NASDAQ futures are DOWN -1.34% (-189 points)
Stock futures are falling in Thursday pre-open as markets are tied to Russian/Ukraine failed negotiations,
European stocks were lower amid a volatile week following U.S. market moves,
Asia-Pacific stocks jumped after oil pricing falls with Japan’s Nikkei 225 jumping nearly 4% to lead regional gains.
Henry’omics:
Negotiations between Russian and Ukrainian foreign ministers ended with little progress on matters including a cease-fire and safe passage of fleeing civilians. <CNBC>
On Wednesday, the Dow rose 653.61 points, or 2%, the S&P 500 climbed 2.6% for its best day since June 2020 and the Nasdaq gained 3.6% for its best day since November 2020.
Economic Data Docket: February’s consumer price index Thursday morning. Economists expect headline inflation rose 0.7% last month, or 7.8% from the year prior.
News (continued): The U.S. FDA has granted orphan drug designation for Intellia’s ex vivo investigational T cell receptor (TCR)-T cell therapy, NTLA-5001, for the treatment of acute myeloid leukemia (AML).
NTLA-5001 is an autologous TCR-T cell therapy designed to target the Wilms’ Tumor (WT1) antigen, which is highly expressed in AML and many other hematologic and solid tumors. NTLA-5001 is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent AML who have previously received first-line therapy.
RegMed Investors’ (RMi) closing bell: “pocket of appreciation, how long will it last? Sentiment is transitory, volatility seems permanent as the cell and gene therapy sector recovers losses and I don’t trust this rally going forward.” … https://www.regmedinvestors.com/articles/12334
Ebb and flow –
· March – 4 negative and 3 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... 24 total to date
Companies in my headlights – It’s your decision; I provide ideas and context:
SELL: for profiting
Agenus (AGEN) closed up +$0.17 after Tuesday’s +$0.02 and Monday’s +$0.01 with a negative -$0.02 or -0.64% pre-open indication
Beam Therapeutics (BEAM) closed up +$2.64 after Tuesday’s -$0.34 to $62,47 with a negative -$0.41 or -0.63% pre-open indication,
Chinook Therapeutics (KDNY) closed up +$0.42 after Tuesday’s $0.26 and Monday’s $0.08, Friday’s -$0.35 and last Thursday’s -$0.41 with a negative -$0.63 or -4.93% pre-open indication
CRISPR Therapeutics (CRSP) closed up +$2.07 after Tuesday’s +$5.15 and Monday’s +$2.01 with a negative -$0.82 or -$1.31% pre-open indication.
Intellia Therapeutics (NTLA) closed up +$2.34 after Tuesday’s +$0.79, Monday’s -$2.18, Friday’s -$5.93, and last Thursday’s -$13.42 with a negative -$0.68 or -1.03% pre-open indication
Ionis Pharmaceuticals (IONS) closed up +$0.98 with a negative -$1.43 or -4.29% pre-open indication.
Voyager Therapeutics (VYGR) closed up again +$1.06 after Tuesday’s +$1.31 or +33.33% with a negative -$0.05 or -0.79% pre-open indication.
Regenxbio (RGNX) closed down -$0.08 after Tuesday’s +$1.71 or +6.21% to $29.24 with a negative -$0.10 or -0.34% pre-open indication and a “tippy” chart.
Sage Therapeutics (FATE) closed up +$0.76 after Tuesday’s -$0.72 and Monday’s +$1.22 with a negative -$0.57 or -1.74% pre-open indication.
Sangamo Therapeutics (SGMO0 closed up +$0.32 with a negative -$0.21 or -3.54% pre-open indication.
Ultragenyx (RARE) closed up +$0.81 after Tuesday’s +$3.85 and Monday’s +$0.22 with a neutral $0.00 pre-open indication.
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed down Wednesday -$0.26 with 1,225 shares traded after Tuesday’s flat (having been up +$0.14) with 1,142 shares traded, Monday’s +$0.29 with 399 shares traded, Friday’s -$0.44 with 1,300 shares traded and last Thursday’s +$0.25 with 487 shares traded, …
WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: I am NOT waiting for a sector reversal for it’s coming.
The cell and gene therapy sector is in for a correction yet, again.
As I stated yesterday, “bounce, baby, bounce”.
Earnings’ reporting on the horizon:
· Athersys (ATHX), Tuesday, 3/15
· Cellectis SA (CLLS) Thursday, 3/22
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
